Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-04-15
2008-04-15
Kemmerer, Elizabeth C. (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000, C530S351000, C514S008100, C514S012200
Reexamination Certificate
active
07358227
ABSTRACT:
The present invention relates to a pharmaceutical composition containing a mixture of stable folding variants of recombinant bone morphogenic proteins (rBMPs) and its use in therapy, especially in the treatment of orthopaedic and dental patients. Specifically, the present invention relates to a pharmaceutical composition containing a mixture of stable folding variants of at least two rBMPs or their monomers or mutants in a suitable carrier system.
REFERENCES:
patent: 4563489 (1986-01-01), Urist
patent: 5399677 (1995-03-01), Wolfman et al.
patent: 5631142 (1997-05-01), Wang et al.
patent: 5854207 (1998-12-01), Lee et al.
patent: 6180606 (2001-01-01), Chen et al.
patent: 6245889 (2001-06-01), Wang et al.
patent: 103278 (1999-05-01), None
patent: WO 92/09697 (1992-06-01), None
patent: WO 93/09229 (1993-05-01), None
patent: WO 00/56879 (2000-09-01), None
patent: WO 00/64460 (2000-11-01), None
DiCesare et al., “Effects of indomethacin on demineralized bone-induced heterotopic ossification in the rat,”J. Orthop. Res., 9:855-861 (1991).
Isobe et al., “Bone Morphogenetic protein encapsulated with a biodegradable and biocompatible polymer,”J. Biomed. Mat. Res., 32:433-438 (1996).
Massagué, “The TGF-β Family of Growth and Differentiation Factors,”Cell, 49:437-438 (1987).
Muthukumaran and Reddi, “Dose-dependence of the threshold for optimal bone induction by collagenous bone matrix and osteogenin-enriched fraction,”Collagen Rel. Res., 8:433-441 (1988).
Ngo et al., “Computational Complexity Protein Structure Prediction, and the Levinthal Paradox,”The Protein Folding Problem and Teriary Structure Prediction, Chapt. 14, pp. 491-495, Eds. Merz and Le Grand, Birkhäuser, Boston, MA (1994).
O'Connor, “Animal models of heterotopic ossification,”Clin. Orthop. 346:71-80 (1998).
Pilbeam et al., “Comparison of the Effects of Various Lengths of Synthetic Human Parathyroid Hormone-Related Peptide . . . ,”Bone,14:717-720 (1993).
Vukicevic et al., “Induction of nephrogenic mesenchyme by osteogenic protein 1 (bone morphogenetic protein 7),”Proc. Natl. Acad. Sci. USA, 93:9021-9026 (1996).
Weber et al., “Disulfide Bridge Conformers of Mature BMP Are Inhibitors for Heterotopic Ossification,”Biochem. and Biophys. Res. Comm., 286:554-558 (2001).
Wells, “Additivity of Mutational Effects of Proteins,”Biochem., 29(37):8509-8517 (1990).
Wozney “Bone Morphogenetic Proteins,”Progress in Growth Factor Research, 1:267-280 (1989).
Wozney and Rosen, “Bone Morphogenetic Protein and Bone Morphogenetic Protein Gene Family in Bone Formation and Repair,”Clin. Ortho. and Rel. Res., 346:26-37 (1998).
Sailer Hermann
Weber Franz
Banner & Witcoff , Ltd.
Kemmerer Elizabeth C.
The University of Zurich
LandOfFree
Pharmaceutical compositions comprising bone morphogenetic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions comprising bone morphogenetic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions comprising bone morphogenetic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2745285